{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T05:10:43Z","timestamp":1780463443910,"version":"3.54.1"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ipilimumab is the first cytotoxic T lymphocyte protein-4 (CTLA-4) inhibitor approved in the United States. However, there is insufficient data on the safety of this drug in elderly patients. This study aimed to identify adverse events (AEs) associated with ipilimumab in elderly patients through the Adverse Event Reporting System (FAERS) database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>This study retrieved adverse event reports related to ipilimumab in elderly patients (\u226565 years) from the first quarter of 2011 to the first quarter of 2025 in the FAERS database. Multiple disproportionality analysis methods were used to detect adverse event signals associated with ipilimumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 18,698 adverse event reports were included. We identified 245 positive signals using four disproportionality methods. Common AEs included malignant neoplasm progression, diarrhea, colitis, pyrexia, rash, adrenal insufficiency, hypophysitis, and immune-mediated enterocolitis. In addition, we also identified some signals not listed on the drug label, such as orchitis, dropped head syndrome, and alopecia areata. Approximately 40% of AEs related to ipilimumab in elderly patients occurred within one month of medication use, with a median onset time of 42 days (interquartile range[IQR] 18-80days). Among these, AEs related to skin and subcutaneous tissue disorders had the shortest median time to onset, while those related to endocrine disorders had the longest median time to onset and continued to occur over time. The weight subgroup analysis indicated a statistically significant difference in the median time to AEs between the &amp;lt;70\u00a0kg and \u226570 kg populations (P&amp;lt;0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study provides safety data on the use of ipilimumab in elderly patients and suggests prioritizing monitoring for gastrointestinal events and endocrine toxicities in elderly patients during treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1689130","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:54:06Z","timestamp":1780462446000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety profile of ipilimumab in elderly patients: a disproportionate analysis based on the FDA Adverse Event Reporting System database"],"prefix":"10.3389","volume":"16","author":[{"given":"Yang","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Affiliated Nanjing Brain Hospital of Nanjing Medical University","place":["Nanjing, China"]},{"name":"Department of Pharmacy, Nanjing Chest Hospital","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Affiliated Nanjing Brain Hospital of Nanjing Medical University","place":["Nanjing, China"]},{"name":"Department of Pharmacy, Nanjing Chest Hospital","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijia","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Affiliated Nanjing Brain Hospital of Nanjing Medical University","place":["Nanjing, China"]},{"name":"Department of Pharmacy, Nanjing Chest Hospital","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinglan","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Affiliated Nanjing Brain Hospital of Nanjing Medical University","place":["Nanjing, China"]},{"name":"Department of Pharmacy, Nanjing Chest Hospital","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Affiliated Nanjing Brain Hospital of Nanjing Medical University","place":["Nanjing, China"]},{"name":"Department of Pharmacy, Nanjing Chest Hospital","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shencun","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nanjing Chest Hospital","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqiao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Guangdong Second Provincial General Hospital of Jinan University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"9659","DOI":"10.3390\/ijms25179659","article-title":"Predictive biomarkers and resistance mechanisms of checkpoint inhibitors in Malignant solid tumors","volume":"25","author":"Pavelescu","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.2668","article-title":"Late-onset immune-related adverse events after immune checkpoint inhibitor therapy","volume":"8","author":"Durbin","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/cac2.12505","article-title":"Management of locally advanced non-small cell lung cancer: State of the art and future directions","volume":"44","author":"Miao","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1439231","article-title":"Association between statin use and immune-related adverse events in patients treated with immune checkpoint inhibitors: Analysis of the Faers database","volume":"15","author":"Yang","year":"2024","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-024-03816-0","article-title":"Immune checkpoint inhibitors-related thyroid dysfunction: Influencing factor analysis, prediction model development, and management strategy proposal","volume":"74","author":"Li","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(24)00264-9","article-title":"Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged \u226570 years or with an Ecog performance status of 2 (Gfpc 08\u20132015 Energy): A randomised, open-label, phase 3 study","volume":"13","author":"L\u00e9na","year":"2025","journal-title":"Lancet Respir Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.13063","article-title":"Toxicity and response to ipilimumab and nivolumab in older patients with metastatic melanoma: A multicentre retrospective analysis","volume":"35","author":"Pathmanathan","year":"2022","journal-title":"Pigment Cell Melanoma Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"21055","DOI":"10.1038\/s41598-025-07287-w","article-title":"Disproportionality analysis of adverse events associated with ipilimumab and nivolumab combination therapy based on Faers database","volume":"15","author":"Dai","year":"2025","journal-title":"Sci Rep"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1186\/s12885-025-14546-6","article-title":"Comparative safety of nivolumab plus ipilimumab versus nivolumab plus relatlimab in advanced melanoma: A pharmacovigilance study based on the Fda adverse event reporting system (Faers)","volume":"25","author":"Xu","year":"2025","journal-title":"BMC Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-024-01713-1","article-title":"Adverse events of nivolumab plus ipilimumab versus nivolumab plus cabozantinib: A real-world pharmacovigilance study","volume":"46","author":"Oka","year":"2024","journal-title":"Int J Clin Pharm"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1631273","article-title":"Evaluating the toxicity profile of combination immune checkpoint inhibitors: A disproportionality analysis of real-world adverse events from the Fda adverse event reporting system for tremelimumab, durvalumab, ipilimumab, and nivolumab","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2024.05.002","article-title":"Nowcasting and forecasting global aging and cancer burden: Analysis of data from the Globocan and global burden of disease study","volume":"4","author":"Li","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.scib.2025.02.006","article-title":"Profiles and disparities of the global cancer and subtypes burden among adults aged 65 years and older: Changing patterns in incidence and mortality, 1990-2021","volume":"70","author":"Li","year":"2025","journal-title":"Sci Bull (Beijing)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.6004\/jnccn.2021.7055","article-title":"Representation and outcomes of older adults in practice-changing oncology trials in the era of novel therapies: A guideline appraisal","volume":"20","author":"Chow","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009258","article-title":"Inclusion, characteristics, and reporting of older adults in Fda registration studies of immunotherapy, 2018-2022","volume":"12","author":"Mac Eochagain","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.07.006","article-title":"Exploring novel adverse events of Nefecon","volume":"9","author":"Wang","year":"2024","journal-title":"Kidney Int Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1485190","article-title":"A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the Faers and Jader databases","volume":"15","author":"Liu","year":"2024","journal-title":"Front Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1558868","article-title":"A real-world pharmacovigilance analysis of omadacycline in Fda adverse event reporting system (Faers) database","volume":"16","author":"Shi","year":"2025","journal-title":"Front Pharmacol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1369384","article-title":"Safety assessment of cenobamate: Real-world adverse event analysis from the Faers database","volume":"15","author":"Chen","year":"2024","journal-title":"Front Pharmacol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1399172","article-title":"Suspected adverse drug reactions of rivaroxaban reported in the United States Food and Drug Administration adverse event reporting system database: A pharmacovigilance study","volume":"15","author":"Wu","year":"2024","journal-title":"Front Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.3390\/biomedicines12081708","article-title":"Adverse event profiles of the third-generation aromatase inhibitors: Analysis of spontaneous reports submitted to Faers","volume":"12","author":"Zhang","year":"2024","journal-title":"Biomedicines"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw696","article-title":"Immune checkpoint inhibitors-related orchitis","volume":"28","author":"Brunet-Possenti","year":"2017","journal-title":"Ann Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2018.03.003","article-title":"Alopecia Areata under Ipilimumab. Annales De Dermatologie Et De Venereologie","volume":"145","author":"Amini-Adle","year":"2018"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: A systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102440","article-title":"Immune checkpoint inhibitor-induced diarrhea and colitis: Incidence and management. A systematic review and meta-analysis","volume":"109","author":"Nielsen","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.768957","article-title":"Mechanisms of immune checkpoint inhibitor-mediated colitis","volume":"12","author":"Westdorp","year":"2021","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1447021","article-title":"Toxicity in the era of immune checkpoint inhibitor therapy","volume":"15","author":"Keam","year":"2024","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"11504","DOI":"10.3390\/ijms241411504","article-title":"Checkpoint inhibitor-induced colitis: From pathogenesis to management","volume":"24","author":"Terrin","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: Long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.92a.24090","article-title":"How should I manage my patient with cancer who is experiencing diarrhea while on immunotherapy","volume":"92","author":"Kundu","year":"2025","journal-title":"Cleve Clin J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: A systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.S224791","article-title":"Managing ipilimumab-induced hypophysitis: Challenges and current therapeutic strategies","volume":"12","author":"Tsoli","year":"2020","journal-title":"Cancer Manag Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of Ctla-4 mediates hypophysitis secondary to administration of Ctla-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: Insights into pathogenesis from an autopsy series","volume":"186","author":"Caturegli","year":"2016","journal-title":"Am J Pathol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1530\/ec-25-0697","article-title":"A systematic review of ipilimumab-induced hypophysitis","volume":"15","author":"Kim","year":"2026","journal-title":"Endocr Connect"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.3390\/jpm13081210","article-title":"Unveiling the etiopathogenic spectrum of hypophysitis: A narrative review","volume":"13","author":"Menotti","year":"2023","journal-title":"J Pers Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2023.100374","article-title":"Autoantibodies involved in primary and secondary adrenal insufficiency following treatment with immune checkpoint inhibitors","volume":"17","author":"Helderman","year":"2023","journal-title":"Immunooncol Technol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.5485","article-title":"Adrenal insufficiency in adults: A review","volume":"334","author":"Vaidya","year":"2025","journal-title":"Jama"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2023.11.003","article-title":"Primary adrenal insufficiency induced by immune checkpoint inhibitors: Biological, clinical, and radiological aspects","volume":"50","author":"Martella","year":"2023","journal-title":"Semin Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1530\/eje-19-0291","article-title":"Immune checkpoint inhibitors and type 1 diabetes mellitus: A case report and systematic review","volume":"181","author":"de Filette","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2023.1785","article-title":"Incidence of endocrine-related dysfunction in patients treated with new immune checkpoint inhibitors: A meta-analysis and comprehensive review","volume":"38","author":"Yoo","year":"2023","journal-title":"Endocrinol Metab (Seoul)"},{"key":"B43","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/eje-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: An Ese clinical practice guideline","volume":"187","author":"Husebye","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011271","article-title":"Hyperglycemia in patients treated with immune checkpoint inhibitors: Key clinical challenges and multidisciplinary consensus recommendations","volume":"13","author":"Wu","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: Esmo clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/857519","article-title":"Immune-mediated adverse events associated with ipilimumab Ctla-4 blockade therapy: The underlying mechanisms and clinical management","volume":"2013","author":"Tarhini","year":"2013","journal-title":"Scientifica (Cairo)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1071983","article-title":"Cutaneous manifestations associated with immune checkpoint inhibitors","volume":"14","author":"Watanabe","year":"2023","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.04.105","article-title":"Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features","volume":"83","author":"Ellis","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.70149","article-title":"Prevention and management of cutaneous immune-related adverse events: Eadv task force statement","volume":"40","author":"Fattore","year":"2025","journal-title":"J Eur Acad Derma"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: Asco guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvac036","article-title":"It's not always siad: Immunotherapy-triggered endocrinopathies enter the field of cancer-related hyponatremia","volume":"6","author":"Bischoff","year":"2022","journal-title":"J Endocr Soc"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.807050","article-title":"Cytokine release syndrome in cancer patients receiving immune checkpoint inhibitors: A case series of 25 patients and review of the literature","volume":"13","author":"Tay","year":"2022","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00557","article-title":"Immune checkpoint inhibitor-related cytokine release syndrome: Analysis of who global pharmacovigilance database","volume":"11","author":"Ceschi","year":"2020","journal-title":"Front Pharmacol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2385489","article-title":"Cytokine release syndrome associated with immune checkpoint inhibitors: A pharmacovigilance study based on spontaneous reports in faers","volume":"24","author":"Xi","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.14740\/wjon2612","article-title":"Demographic variations in immune checkpoint inhibitor adverse events: A real-world study","volume":"16","author":"Shambhavi","year":"2025","journal-title":"World J Oncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12885-025-15391-3","article-title":"Hematological toxicity of immune checkpoint inhibitors: A pharmacovigilance study","volume":"26","author":"Tan","year":"2025","journal-title":"BMC Cancer"},{"key":"B57","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1016\/s1470-2045(24)00404-2","article-title":"Management of immune checkpoint inhibitor-associated toxicities in older adults with cancer: Recommendations from the International Society of Geriatric Oncology (Siog)","volume":"26","author":"Eochagain","year":"2025","journal-title":"Lancet Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1689130\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:54:16Z","timestamp":1780462456000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1689130\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":57,"alternative-id":["10.3389\/fonc.2026.1689130"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1689130","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"article-number":"1689130"}}